Literature DB >> 26528782

Generation of Recombinant Vaccinia Viruses.

Linda S Wyatt1, Patricia L Earl1, Bernard Moss1.   

Abstract

This unit describes how to infect cells with vaccinia virus and then transfect them with a plasmid-transfer vector or PCR fragment to generate a recombinant virus. Selection and screening methods used to isolate recombinant viruses and a method for the amplification of recombinant viruses are described. Finally, a method for live immunostaining that has been used primarily for detection of recombinant modified vaccinia virus Ankara (MVA) is presented.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Mesh：

Year:  2015        PMID： 26528782      PMCID： PMC5123791          DOI： 10.1002/9780471729259.mc14a04s39

Source DB:  PubMed          Journal:  Curr Protoc Microbiol


  27 in total

1.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain.

Authors:  F Scheiflinger; F G Falkner; F Dorner
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses.

Authors:  M W Carroll; B Moss
Journal:  Biotechniques       Date:  1995-09       Impact factor: 1.993

4.  A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells.

Authors:  D D Patel; C A Ray; R P Drucker; D J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts.

Authors:  M Pfleiderer; F G Falkner; F Dorner
Journal:  J Gen Virol       Date:  1995-12       Impact factor: 3.891

7.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

8.  A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

Authors:  G Sutter; L S Wyatt; P L Foley; J R Bennink; B Moss
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

9.  Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Authors:  Linda S Wyatt; Patricia L Earl; Wei Xiao; Jeffrey L Americo; Catherine A Cotter; Jennifer Vogt; Bernard Moss
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

10.  One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription.

Authors:  C Bertholet; R Drillien; R Wittek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205
View more
  5 in total

1.  Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.

Authors:  Rakesh Kulkarni; Wen-Ching Chen; Ying Lee; Chi-Fei Kao; Shiu-Lok Hu; Hsiu-Hua Ma; Jia-Tsrong Jan; Chun-Che Liao; Jian-Jong Liang; Hui-Ying Ko; Cheng-Pu Sun; Yin-Shoiou Lin; Yu-Chiuan Wang; Sung-Chan Wei; Yi-Ling Lin; Che Ma; Yu-Chan Chao; Yu-Chi Chou; Wen Chang
Journal:  PLoS One       Date:  2021-09-09       Impact factor: 3.752

2.  Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.

Authors:  Yvon Deschambault; Jessie Lynch; Bryce Warner; Kevin Tierney; Denise Huynh; Robert Vendramelli; Nikesh Tailor; Kathy Frost; Babu Sajesh; Kyle LeBlanc; Christine Layne; Lisa Lin; Levi Tamming; Daniel Beniac; Stephanie Booth; Michael Carpenter; David Safronetz; Xuguang Li; Darwyn Kobasa; Jingxin Cao
Journal:  J Virol       Date:  2022-04-12       Impact factor: 6.549

Review 3.  Recombinant Ranaviruses for Studying Evolution of Host-Pathogen Interactions in Ectothermic Vertebrates.

Authors:  Jacques Robert; James K Jancovich
Journal:  Viruses       Date:  2016-07-06       Impact factor: 5.048

4.  Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.

Authors:  Linda S Wyatt; Wei Xiao; Jeffrey L Americo; Patricia L Earl; Bernard Moss
Journal:  mBio       Date:  2017-06-06       Impact factor: 7.867

5.  Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.

Authors:  Matthew R Schuelke; Phonphimon Wongthida; Jill Thompson; Timothy Kottke; Christopher B Driscoll; Amanda L Huff; Kevin G Shim; Matt Coffey; Jose Pulido; Laura Evgin; Richard G Vile
Journal:  J Immunother Cancer       Date:  2019-07-17       Impact factor: 13.751
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.